Holen Sie sich die Stockscreener-App
4.45
2.41%
-0.11
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
The share offer capped at $230M has expired. Arbutus (ABUS) announces final results. - Stock Titan
Arbutus Biopharma (ABUS) Shares Rise on $230M Share Buyback Comp - GuruFocus
An up-to-$230M share offer expired; Arbutus Biopharma (ABUS) announced preliminary results. - Stock Titan
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewswire
About 23% of Arbutus shares are being bought back for $230 million. - Stock Titan
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Stocktwits
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com - Investing.com Nigeria
ABUS Stock Price, Quote & Chart - ChartMill
Arbutus Biopharma Corp (ABUS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
An 8% holder now reports a passive stake in Arbutus Biopharma (ABUS) - stocktitan.net
Arbutus Biopharma Corp (ABUS) Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma Corp (ABUS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arbutus Biopharma Corp (ABUS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Quantum BioPharma Ltd Peer Comparison – Compare with Others - Value Research
Cronos Group Inc. Common Share (CRON) Peer Comparison – Compare with Others - Value Research
Acasti Pharma Inc. Class AADR Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Fed. Circ. Agrees To Speed Up Args In COVID Vax Patent Case - Law360
Arbutus Biopharma (NASDAQ:ABUS) Capital Strategy Draws Attention - Kalkine Media
Why Is Arbutus Biopharma Stock Gaining Friday? - TradingView
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet - StocksToTrade
Arbutus Biopharma Announces $230 Million Modified Dutch Auction Tender Offer for Shares - Kalkine Media
Why is Arbutus Biopharma stock surging today? - Investing.com India
Why is Arbutus Biopharma stock surging today? By Investing.com - Investing.com UK
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Stocktwits
ABUS Looks 90.4% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
Arbutus Biopharma stock surges on $230M buyback plan - Investing.com
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
ABUS Looks 90.4% Undervalued on GF Value™ - GuruFocus
Arbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender Offer - Quiver Quantitative
Arbutus Announces Intent to Repurchase Up to US$230 Million - GlobeNewswire
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified 'Dutch Auction” Tender Offer - The Manila Times
Arbutus Biopharma Corporation authorizes a Buyback Plan. - marketscreener.com
Arbutus Plans $230 Million Share Buyback After Moderna Deal - MyChesCo
Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims - Law360
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130 - TradingKey
Moderna Vaccine Appeal Poised to Set Patent Liability Benchmark - Bloomberg Law News
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - Stock Titan
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Arbutus Biopharma earnings matched, revenue topped estimates - Investing.com
Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact - Kalkine Media
ABUS Looks 90.7% Undervalued on GF Value™ Despite Revenue Challe - GuruFocus
What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings - GuruFocus
Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com - Investing.com Nigeria
Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary - TradingView
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Arbutus: Q2 Earnings Snapshot - KVUE
Arbutus Biopharma (ABUS) swings to $164.6M H1 profit on $178.4M Moderna payout - Stock Titan
American Public Education and Arbutus Biopharma Post Notable Stock Returns - MarketsMojo
Arbutus Biopharma (ABUS) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - Yahoo Finance
Arbutus Biopharma Corp (I9DN.DU) stock price, news, quote and history - Yahoo Finance Australia
Arbutus Biopharma Corp (I9DN.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arbutus Biopharma (ABUS) Institutional Ownership 2026 - MarketBeat
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):